Verisante Technology Inc., a company that deals with cancer detection technology, has announced that Verisante’s Aura™ — the revolutionary skin cancer detection device — has been named a finalist for the 2013 Prism Awards in the Life Sciences and Biophotonics category.
“We are honored to be a finalist for this prestigious Award,” said Thomas Braun, President and CEO. “It is very gratifying to be recognized as an industry leader for our innovative and disruptive technology, which has the potential to improve patient outcomes, reduce wait times and also save the health care system time and money. The Aura is a game changing technology because in half a second it will tell doctors if a suspicious skin lesion is high or low risk for being cancerous and should be biopsied or not.”
The Verisante Aura™ beta units are currently installed at five leading dermatology clinics across Canada for software verification purposes. This is the final step prior to making this device available in Canada, 27 European countries, and Australia where the device has already been approved for sale. The Verisante Aura™ is expected to be commercially available in Canada, Europe and Australia in early 2013.
The Prism Awards, named the “Photonics Oscar” by OptecNet Deutschland, is a celebration of the best of the industry. It takes place every year in conjunction with SPIE Photonics West in San Francisco, California.
The Prism Awards for Photonics Innovation is a leading international competition that honors the best new photonic products on the market. Over the years, the Prism Awards has received applications from more than 35 countries across the globe. Applications are judged by panel of leading industry experts, venture capitalists, luminaries and visionaries.
SPIE Photonics West is the world’s largest and most influential photonics and optics event with over 1500 companies exhibiting and 20,000 attendees.
Click here for the complete issue.